The CJC 1295 ipamorelin sermorelin stack combines three growth hormone secretagogues. Compare dosing, timing, benefits, and safety in this research overview.
The CJC 1295, ipamorelin, and sermorelin stack is a research combination of three growth hormone secretagogues that signal the pituitary through two different receptor families. CJC 1295 and sermorelin are growth hormone-releasing hormone (GHRH) analogs, while ipamorelin is a selective ghrelin receptor agonist. None of the three peptides is FDA-approved for human use in the United States, and all are sold for laboratory research only.
What Is the CJC 1295 Ipamorelin Sermorelin Stack?
This stack layers a long-acting GHRH analog, a short-acting GHRH fragment, and a ghrelin mimetic into one protocol. The goal described in the research literature is a larger, more natural-looking growth hormone pulse than any single peptide produces alone.
Anyone who has looked into what is cjc-1295 ipamorelin will recognize the reasoning: that two-peptide version is already one of the most studied GH combinations in animal models and small human trials. Adding sermorelin is an attempt to fine-tune pulse timing and amplitude.
Researchers generally separate the compounds by how they behave:
- CJC 1295 with DAC: a long half-life version that keeps GHRH signaling elevated for days.
- CJC 1295 without DAC (mod GRF 1-29): a shorter form designed to mimic natural pulses.
- Ipamorelin: a ghrelin receptor agonist that, in animal studies, raises cortisol and prolactin far less than older secretagogues.
- Sermorelin: the first 29 amino acids of GHRH, studied in humans since the 1980s.
How the Three Peptides Differ
Each compound has a different half-life, receptor target, and release pattern, so stacking them is not the same as taking a larger dose of one peptide.
| Compound | Receptor Target | Approximate Half-Life | Release Pattern |
|---|---|---|---|
| CJC 1295 with DAC | GHRH receptor | About 6–8 days | Continuous elevation |
| CJC 1295 without DAC | GHRH receptor | About 30 minutes | Pulsatile |
| Ipamorelin | Ghrelin receptor (GHS-R1a) | About 2 hours | Pulsatile |
| Sermorelin | GHRH receptor | About 10–20 minutes | Pulsatile |
Because the DAC version stays active for days, it flattens the body's natural rhythm. Sermorelin and ipamorelin clear quickly, which preserves pulsatile release. Mixing a long-acting agent with short-acting ones is a design choice, not a strategy with proven human outcomes.
Dosing and Timing Considerations
No FDA-approved human dose exists for this stack, and published protocols vary widely. Most discussion centers on whether to dose once daily or split the dose, and whether fasting before administration changes the response.
The best time to take cjc 1295 ipamorelin is usually described as right before sleep, when natural growth hormone release peaks. Adding sermorelin inside that same window is meant to amplify one pulse instead of creating a competing one.
Guides on how to inject cjc 1295 ipamorelin generally describe subcutaneous injection with a small insulin syringe and rotating injection sites. Sterile technique matters, and sharing vials is a known contamination risk.
Common points of debate among researchers:
- Whether eating before dosing blunts the growth hormone response, which appears more likely with ghrelin mimetics.
- Whether CJC 1295 with DAC belongs in the same protocol as short-acting peptides.
- Whether sermorelin adds anything meaningful beyond ipamorelin at typical research doses.
Comparing the Stack With Other Peptide Combinations
Several related combinations come up in the same conversations. The table below summarizes how they differ in focus.
| Combination | Primary Research Focus | Notes |
|---|---|---|
| CJC 1295 + ipamorelin | Pulsatile GH release | Most common pairing in research |
| CJC 1295 + ipamorelin + sermorelin | Layered GHRH and ghrelin signaling | No controlled human trials of the trio |
| CJC 1295 + tesamorelin | GHRH-only, long-acting approach | Tesamorelin is FDA-approved for one specific condition |
| CJC 1295 + ipamorelin + AOD 9604 | GH release plus a GH fragment | AOD 9604 is not a secretagogue |
| CJC 1295 + ipamorelin + IGF-1 LR3 | Upstream plus downstream signaling | IGF-1 LR3 bypasses the pituitary entirely |
Questions about cjc-1295 ipamorelin vs tesamorelin usually come down to purpose. Tesamorelin is approved by the FDA for reducing visceral fat in adults with HIV-associated lipodystrophy, while the CJC 1295 and ipamorelin pair has no approved human indication.
Muscle Growth, Fat Loss, and Body Composition Claims
Most claims about cjc 1295 ipamorelin muscle growth come from rodent studies, small trials, and anecdotal reports rather than large randomized human trials. Growth hormone and IGF-1 do affect lean mass and fat mass, but supraphysiological levels also carry real risks.
Reported outcomes in the research literature include modest gains in lean mass, small reductions in fat mass, and better sleep quality. Sermorelin's own clinical trials focused largely on children with growth hormone deficiency, not adult body composition.
Sustained GH elevation is associated with joint pain, fluid retention, insulin resistance, and in extreme cases acromegaly-like changes. Body composition changes from any GH secretagogue are slow and are not comparable to anabolic steroids.
Safety, Side Effects, and Legal Status
CJC 1295, ipamorelin, and sermorelin are not FDA-approved for general human use. Ipamorelin and CJC 1295 are sold as research chemicals, which means purity and dosing accuracy are not guaranteed by any regulator.
Reported side effects include injection site reactions, headache, flushing, dizziness, increased appetite, water retention, and fatigue. Continuous GHRH stimulation may desensitize the pituitary, and the long-term effects of chronic use are unknown.
Anyone considering these peptides should speak with a licensed healthcare professional and treat online protocols as unverified information rather than medical guidance.
For now, the CJC 1295, ipamorelin, and sermorelin stack remains an experimental research combination with no approved medical use and no controlled human safety data.
RELATED PEPTIDE TOPICresearch peptide IpamorelinFrequently Asked Questions
What is the CJC 1295 ipamorelin sermorelin stack?
It is a research combination of three growth hormone secretagogues: CJC 1295 and sermorelin, which are GHRH analogs, plus ipamorelin, which activates the ghrelin receptor. The idea is to stimulate growth hormone release through two separate pathways at once. None of the three peptides is FDA-approved for human use, so the stack is not a recognized medical treatment.
Is the CJC 1295 ipamorelin sermorelin stack safe?
There are no controlled human safety trials of this three-peptide combination, so its risk profile is not established. Reported side effects of GH secretagogues include injection site reactions, headache, flushing, water retention, joint pain, and possible insulin resistance. Anyone considering these compounds should discuss them with a licensed healthcare professional first.
How much CJC 1295 and ipamorelin should I take with sermorelin?
There is no standardized human dose for this stack because it is not FDA-approved for human use, and online protocols vary widely. Research doses are typically described in micrograms and often dosed before sleep, but those numbers come from laboratory and anecdotal sources rather than regulatory guidance. Do not self-dose; consult a qualified clinician instead.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.